Novartis | Brutto Fortjeneste På Salg

Gross Profit On Sales Endring Dato
AbbVie USD 8.22B 1.35B 2024-03
Alcon AG USD 1.38B 98M 2024-03
Almirall EUR 158.6M 163.75M 2024-03
Amgen USD 4.25B 837M 2024-03
AstraZeneca USD 10.46B 718M 2024-03
Bayer EUR 8.3B 926M 2024-03
Biogen USD 1.75B 19.7M 2024-03
Bristol-Myers Squibb USD 8.93B 163M 2024-03
Eli Lilly USD 7.09B 470.9M 2024-03
Fresenius EUR 1.41B 109M 2024-03
Fresenius Medical Care EUR 1.17B 176.35M 2024-03
Galapagos EUR 59.88M 70.76M 2024-03
Genmab DKK 3.96B 594M 2024-03
Gilead Sciences USD 5.13B 370M 2024-03
GlaxoSmithKline GBP 5.39B 326M 2024-03
GRIFOLS EUR 689.83M 58M 2023-12
Hikma Pharmaceutical USD 733M 91M 2023-06
J&J USD 14.87B 275M 2024-03
Lonza CHF 1.11B 134M 2023-06
Merck EUR 3.01B 2M 2024-03
Merck USD 12.24B 945M 2024-03
Novartis USD 9.02B 235M 2024-03
Novartis USD 9.02B 235M 2024-03
Orion EUR 170.6M 700K 2024-03
Pfizer USD 11.5B 3.92B 2024-03
Philips EUR 1.82B 16M 2024-03
Recordati EUR 415.56M 82.2M 2024-03
Regeneron Pharmaceuticals USD 2.71B 206.1M 2024-03
Roche Holding CHF 22.16B 123M 2023-06
Sanofi EUR 7.68B 1.18B 2024-03
UCB EUR 1.79B 24M 2023-06



Novartis Brutto Fortjeneste På Salg - Gjeldende verdier, historiske data, prognoser, statistikk, diagrammer og økonomiske kalender - Jun 2024.